vTv Therapeutics Inc (VTVT) - Total Liabilities
Based on the latest financial reports, vTv Therapeutics Inc (VTVT) has total liabilities worth $8.85 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset growth rate of vTv Therapeutics Inc to track the company's year-over-year net asset growth rate.
vTv Therapeutics Inc - Total Liabilities Trend (2013–2025)
This chart illustrates how vTv Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. See VTVT cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
vTv Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of vTv Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hanyang Digitech Co. Ltd
KQ:078350
|
Korea | ₩148.78 Billion |
|
Servotronics Inc
NYSE MKT:SVT
|
USA | $13.01 Million |
|
Megaforce Co Ltd
TWO:3294
|
Taiwan | NT$2.57 Billion |
|
Zhong Yang Technology Co Ltd
TW:6668
|
Taiwan | NT$1.52 Billion |
|
Torimbia Socimi S.A.
MC:YTRM
|
Spain | €89.87 Million |
|
Nelly Group AB
ST:NELLY
|
Sweden | Skr547.40 Million |
|
enGene Holdings Inc. Common Stock
NASDAQ:ENGN
|
USA | $52.36 Million |
|
Dongsung Corporation
KO:102260
|
Korea | ₩501.16 Billion |
Liability Composition Analysis (2013–2025)
This chart breaks down vTv Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see VTVT market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 14.36 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.10 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.09 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how vTv Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for vTv Therapeutics Inc (2013–2025)
The table below shows the annual total liabilities of vTv Therapeutics Inc from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $25.46 Million | +6.25% |
| 2024-12-31 | $23.96 Million | -18.95% |
| 2023-12-31 | $29.57 Million | +7.91% |
| 2022-12-31 | $27.40 Million | +167.26% |
| 2021-12-31 | $10.25 Million | -6.77% |
| 2020-12-31 | $11.00 Million | -39.27% |
| 2019-12-31 | $18.11 Million | -80.19% |
| 2018-12-31 | $91.41 Million | -48.92% |
| 2017-12-31 | $178.96 Million | +23.05% |
| 2016-12-31 | $145.44 Million | -14.20% |
| 2015-12-31 | $169.50 Million | -66.88% |
| 2014-12-31 | $511.76 Million | +60.31% |
| 2013-12-31 | $319.24 Million | -- |
About vTv Therapeutics Inc
vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company… Read more